198 related articles for article (PubMed ID: 33633036)
1. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Kumar P; Johnson M; Molina JM; Rizzardini G; Cahn P; Bickel M; Wan H; Xu ZJ; Morais C; Sklar P; Greaves W;
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):801-805. PubMed ID: 33633036
[TBL] [Abstract][Full Text] [Related]
2. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Johnson M; Kumar P; Molina JM; Rizzardini G; Cahn P; Bickel M; Mallolas J; Zhou Y; Morais C; Kumar S; Sklar P; Hanna GJ; Hwang C; Greaves W;
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):463-472. PubMed ID: 30985556
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; Klopfer SO; Grandhi A; Eves K; Hepler D; Robertson MN; Hwang C; Hanna GJ; Correll T
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):68-72. PubMed ID: 35972855
[TBL] [Abstract][Full Text] [Related]
4. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H
Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C; Molina JM; Cahn P; Lombaard J; Supparatpinyo K; Kumar S; Campbell H; Wan H; Teal V; Jin Xu Z; Asante-Appiah E; Sklar P; Teppler H; Lahoulou R;
Lancet HIV; 2024 Feb; 11(2):e75-e85. PubMed ID: 38141637
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Nelson M; Winston A; Hill A; Mngqibisa R; Bassa A; Orkin C; Rassool M; Rodgers A; Teal V; Kumar S; Teppler H
AIDS; 2021 Apr; 35(5):759-767. PubMed ID: 33587439
[TBL] [Abstract][Full Text] [Related]
7. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
[TBL] [Abstract][Full Text] [Related]
8. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
[TBL] [Abstract][Full Text] [Related]
9. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
11. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Orkin C; Molina JM; Lombaard J; DeJesus E; Rodgers A; Kumar S; Martin E; Hanna G; Hwang C
Clin Infect Dis; 2020 Mar; 70(7):1344-1352. PubMed ID: 31121015
[TBL] [Abstract][Full Text] [Related]
12. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
PLoS One; 2014; 9(5):e96187. PubMed ID: 24825167
[TBL] [Abstract][Full Text] [Related]
13. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM; Rizzardini G; Orrell C; Afani A; Calmy A; Oka S; Hinestrosa F; Kumar P; Tebas P; Walmsley S; Grandhi A; Klopfer S; Gendrano I; Eves K; Correll TA; Fox MC; Kim J
Lancet HIV; 2024 Jun; 11(6):e369-e379. PubMed ID: 38734015
[TBL] [Abstract][Full Text] [Related]
14. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.
Anderson MS; Gilmartin J; Fan L; Yee KL; Kraft WK; Triantafyllou I; Reitmann C; Guo Y; Liu R; Iwamoto M
Antivir Ther; 2019; 24(6):443-450. PubMed ID: 31433304
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
Pyadushkina E; Derkach E; Rozenberg V; Ugrekhelidze D; Lobodina A; Baxter C; Beyer A
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1215-1220. PubMed ID: 36154357
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
20. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
